See also this year's filing and all EDGAR filings for this company.
PDF Report 0001048477_2016_Biomarin_Pharmaceutical_INC.pdf
Logs
| warning | Large missing amount for aggregate "Revenues" added to remainder. | industry.us_generic | {'missing_ratio': 2.0, 'aggregate_val': -1116854000, 'exp_sum': 1116854000, 'exp_to_value': {'remainder_Revenues': 1116854000}} |
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 2.630510148141688, 'aggregate_val': 2331107000, 'exp_sum': 642088000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 209620000, 'SellingGeneralAndAdministrativeExpense': 476593000, 'ResearchAndDevelopmentExpense': 661905000, 'remainder_Expenses': -706030000}} |
Graph
Absolute values for 0001048477, Biomarin Pharmaceutical INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 1,089,639,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 881,035,000 |
| 2 | PropertyPlantAndEquipmentNet | 704,207,000 |
| 3 | remainder_Assets | 1,054,487,000 |
| 4 | LiabilitiesCurrent | 445,457,000 |
| 5 | LiabilitiesNoncurrent | 44,588,000 |
| 6 | remainder_Liabilities | 838,476,000 |
| 7 | CostOfGoodsAndServicesSold | 162,125,351 |
| 8 | SellingGeneralAndAdministrativeExpense | 489,879,734 |
| 9 | ResearchAndDevelopmentExpense | 1,325,791,621 |
| 10 | remainder_Expenses | -93,621,198 |
| 11 | remainder_Revenues | 966,911,560 |
| 12 | remainder_NetIncome | 5,272,932 |
| 13 | remainder_ComprehensiveNetIncome | 13,607,459 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 3,729,368,000 |
| 1 | Liabilities | 1,328,521,000 |
| 2 | Expenses | 1,884,175,508 |
| 3 | Revenues | 966,911,560 |
| 4 | StockholdersEquity | 2,400,847,000 |
| 5 | NetIncome | -911,991,016 |
| 6 | ComprehensiveNetIncome | -905,187,286 |
| 7 | BaseVar | 3,963,928,230 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 1.71 |
| 9 | EconomicCapitalRatio | 2.83 |
Edgar->Model Mapping
Feature Distribution
Change over Time
